膀胱がん治療薬の世界市場レポート 2025年

膀胱がん治療薬市場規模は、今後数年で急成長が見込まれます。2029年には81億7,000万米ドルに成長し、CAGRは13.4%となります。予測期間の成長は、継続的な研究開発、新興国市場、ヘルスケアインフラ開拓、戦略的提携、共同研究に起因すると考えられます。予測期間の主な動向には、精密医療、免疫療法と標的療法、個別化医療、臨床試験と医薬品パイプライン、併用療法、バイオマーカー主導型治療、遠隔医療と遠隔モニタリング、患者中心の医療などが含まれます。

膀胱がん治療薬市場は、膀胱がん患者数の顕著な増加により需要が急増しています。この急増の要因としては、不衛生な環境での職業曝露、喫煙習慣の増加、ヒ素に汚染された水の摂取などが挙げられます。米国がん協会の2023年のデータによると、米国で新たに膀胱がんと診断された症例は82,290例と推定されています。男性では約62,420例、女性では約19,870例であり、この罹患率の増加が膀胱がん治療薬の需要を煽り、市場の成長をもたらしています。

製薬業界の成長は、今後数年間の膀胱がん治療薬市場の成長を牽引すると予想されます。製薬業界は、政府機関や民間企業による医薬品や医薬品の発見、開発、製造を包含しており、膀胱がん治療の進歩に重要な役割を果たしています。業界の拡大は、革新的な治療法の研究開発および投資を促し、膀胱がんに対する効果的で的を絞った幅広い治療選択肢をもたらします。例えば、2023年6月、ベルギーに本部を置く製薬業界を代表する業界団体である欧州製薬団体連合会（EFPIA）は、2022年の欧州における医薬品総生産額が3,842億米ドル（3,400億ユーロ）に達し、2021年の3,663億米ドル（3,240億ユーロ）から4.95％増加したと報告しました。このような製薬業界の成長は、膀胱がん治療薬の進歩を支え、市場をさらに促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界膀胱がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の膀胱がん治療薬市場：成長率分析
• 世界の膀胱がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の膀胱がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界膀胱がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の膀胱がん治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非筋層浸潤性膀胱がん
• 筋層浸潤性膀胱がん
• 世界の膀胱がん治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低悪性度腫瘍
• 高悪性度腫瘍
• 世界の膀胱がん治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の膀胱がん治療薬市場非筋層浸潤性膀胱がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 膀胱内療法
• 免疫療法薬
• 化学療法薬
• カルメット・ゲラン桿菌（BCG）療法
• 世界の膀胱がん治療薬市場筋層浸潤性膀胱がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法薬
• 免疫療法薬
• 標的治療薬
• 術前療法と術後療法

第7章 地域別・国別分析

• 世界の膀胱がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の膀胱がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 膀胱がん治療薬市場：競合情勢
• 膀胱がん治療薬市場：企業プロファイル
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Celgene Corporation（a subsidiary of Bristol-Myers Squibb Company）Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Sanofi S.A.
• F. Hoffmann-La Roche Ltd.
• Novartis International AG
• Johnson & Johnson
• Merck & Co. Inc.
• Vault Pharma Inc.
• Vyriad Inc.
• Boehringer Ingelheim International GmbH
• Bayer AG
• Asieris Pharmaceuticals Co. Ltd.
• Asana BioSciences LLC
• Array BioPharma Inc.
• Archivel Farma S.L.
• AndroScience Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 膀胱がん治療薬市場2029：新たな機会を提供する国
• 膀胱がん治療薬市場2029：新たな機会を提供するセグメント
• 膀胱がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The bladder cancer drugs market encompasses the sales of medications specifically designed for the treatment of bladder cancer. Bladder cancer, characterized by the development of cancerous tissue in the bladder lining, comprises different types, including urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and others. These malignant growths, also referred to as tumors, can potentially metastasize to adjacent cells and tissues if not promptly addressed.

Bladder cancer drugs are categorized into two main types such as non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer. NMIBC pertains to cancer that originates in the bladder's inner lining, without affecting the bladder muscle. These drugs are used to address various applications, including the treatment of low-grade and high-grade tumors. The distribution of these medications occurs through diverse channels, including hospital pharmacies, retail pharmacies, and other relevant avenues.

The bladder cancer drugs market research report is one of a series of new reports from The Business Research Company that provides bladder cancer drugs market statistics, including bladder cancer drugs industry global market size, regional shares, competitors with a bladder cancer drugs market share, detailed bladder cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the bladder cancer drugs industry. This bladder cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bladder cancer drugs market size has grown rapidly in recent years. It will grow from $4.26 billion in 2024 to $4.94 billion in 2025 at a compound annual growth rate (CAGR) of 16.0%. The growth in the historic period can be attributed to increasing incidence, advancements in drug development, improved diagnostic techniques, aging population, regulatory approvals, patient advocacy and awareness.

The bladder cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $8.17 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to ongoing research and development, emerging markets, healthcare infrastructure development, strategic alliances and collaborations. Major trends in the forecast period include precision medicine, immunotherapy and targeted therapies, personalized medicine, clinical trials and drug pipeline, combination therapies, biomarker-driven treatments, telemedicine and remote monitoring, patient-centric care.

The bladder cancer drugs market has experienced an uptick in demand due to a noticeable increase in the number of bladder cancer cases. Factors contributing to this surge include occupational exposure to unhygienic environments, a rise in smoking habits, and the consumption of water contaminated with arsenic. According to the American Cancer Society's data for 2023, there have been an estimated 82,290 newly diagnosed cases of bladder cancer in the United States. This growing incidence, with about 62,420 cases occurring in men and 19,870 in women, has fueled the demand for bladder cancer drugs, resulting in market growth.

The growing pharmaceutical industry is expected to drive the growth of the bladder cancer drugs market in the coming years. The pharmaceutical sector, which encompasses the discovery, development, and production of drugs and medicines by both government and private organizations, plays a critical role in the advancement of bladder cancer treatments. The industry's expansion encourages research, development, and investment in innovative therapies, leading to a wider range of effective and targeted treatment options for bladder cancer. For instance, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry, reported that total pharmaceutical production in Europe reached $384.2 billion (€340 billion) in 2022, marking a 4.95% increase from $366.3 billion (€324 billion) in 2021. This growth in the pharmaceutical industry supports the advancement of bladder cancer drugs, further propelling the market.

Prominent organizations are making substantial investments in research to leverage nanotechnology as a method for precise drug delivery within the human body. Nanotechnology involves the controlled manipulation of size and shape at the nanometer scale to design, produce, and employ devices, structures, and systems. This innovative drug delivery approach has significant implications for the treatment of bladder cancer, allowing healthcare professionals to administer a highly targeted and efficient treatment that directly attacks cancerous cells while sparing healthy ones. An illustrative example of this is the Center for Drug Research and Development in Canada, which has pledged a $1.2 million investment in Sitka Biopharma to support the development of STK-01, a nanotechnology-based product for bladder cancer treatment, with a focus on advancing clinical trials.

A noteworthy trend gaining traction in the bladder cancer drug market is the application of gene therapy. Gene therapy is a medical approach that addresses or prevents diseases by correcting the underlying genetic issues in a person's genetic makeup. An emblematic development in this field occurred in December 2022 when the US Food and Drug Administration (FDA) granted approval for Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector-based gene therapy. This approval was specific to its utilization in adult patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) presenting carcinoma in situ (CIS) with or without papillary tumors.

In August 2022, Merck & Co., a distinguished pharmaceutical company based in the United States, completed the acquisition of Seagen in a significant deal valued at $40 billion. This strategic acquisition allows Merck & Co. to enhance its presence in the field of oncology. Seagen Inc., the acquired company, is a prominent US-based biotechnology enterprise specializing in the development of various cancer drugs, including treatments for bladder cancer.

Major companies operating in the bladder cancer drugs market include Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), AstraZeneca PLC, GlaxoSmithKline PLC, Sanofi S.A., F. Hoffmann-La Roche Ltd., Novartis International AG, Johnson & Johnson, Merck & Co. Inc., Vault Pharma Inc., Vyriad Inc., Boehringer Ingelheim International GmbH, Bayer AG, Asieris Pharmaceuticals Co. Ltd., Asana BioSciences LLC, Array BioPharma Inc., Archivel Farma S.L., AndroScience Corporation, Amgen Inc., Altor Bioscience Corporation, Alligator Bioscience AB, Adaptimmune Therapeutics PLC, UroGen Pharma Ltd., Seagen Inc., Incyte Corporation, Mayo Foundation for Medical Education and Research, AbbVie Inc., Eisai Co. Ltd., Ipsen S.A., Janssen Pharmaceutica NV, Kyowa Kirin Co. Ltd., Menarini Group, Ono Pharmaceutical Co. Ltd., Pierre Fabre S.A., Taiho Pharmaceutical Co. Ltd.

North America was the largest region in the bladder cancer drugs market in 2024. The Middle East is expected to be the fastest-growing region in the bladder cancer drugs market during the forecast period. The regions covered in the bladder cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the bladder cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The bladder cancer drugs refer to drugs or medications that are used in the treatment of bladder cancer drugs. Bladder cancer is cancerous tissue that occurs on the lining of the bladder. These cancerous tissues are also called tumors, and they have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments for bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and others.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bladder Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bladder cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bladder cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bladder cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Non-Muscle-Invasive Bladder Cancer; Muscle-Invasive Bladder Cancer
• 2) By Application: Low-Grade Tumors; High-Grade Tumors
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
• Subsegments:
• 1) By Non-Muscle-Invasive Bladder Cancer: Intravesical Therapy; Immunotherapy Drugs; Chemotherapy Drugs; Bacillus Calmette-Guerin (BCG) Therapy
• 2) By Muscle-Invasive Bladder Cancer: Chemotherapy Drugs; Immunotherapy Drugs; Targeted Therapy Drugs; Neoadjuvant and Adjuvant Therapy
• Companies Mentioned: Eli Lilly and Company; Bristol-Myers Squibb Company; Pfizer Inc.; Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company); AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bladder Cancer Drugs Market Characteristics

3. Bladder Cancer Drugs Market Trends And Strategies

4. Bladder Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Bladder Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bladder Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bladder Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Bladder Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bladder Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bladder Cancer Drugs Total Addressable Market (TAM)

6. Bladder Cancer Drugs Market Segmentation

• 6.1. Global Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Muscle-Invasive Bladder Cancer
• Muscle-Invasive Bladder Cancer
• 6.2. Global Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low-Grade Tumors
• High-Grade Tumors
• 6.3. Global Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.4. Global Bladder Cancer Drugs Market, Sub-Segmentation Of Non-Muscle-Invasive Bladder Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravesical Therapy
• Immunotherapy Drugs
• Chemotherapy Drugs
• Bacillus Calmette-Guerin (BCG) Therapy
• 6.5. Global Bladder Cancer Drugs Market, Sub-Segmentation Of Muscle-Invasive Bladder Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Drugs
• Immunotherapy Drugs
• Targeted Therapy Drugs
• Neoadjuvant and Adjuvant Therapy

7. Bladder Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Bladder Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bladder Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bladder Cancer Drugs Market

• 8.1. Asia-Pacific Bladder Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bladder Cancer Drugs Market

• 9.1. China Bladder Cancer Drugs Market Overview
• 9.2. China Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bladder Cancer Drugs Market

• 10.1. India Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bladder Cancer Drugs Market

• 11.1. Japan Bladder Cancer Drugs Market Overview
• 11.2. Japan Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bladder Cancer Drugs Market

• 12.1. Australia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bladder Cancer Drugs Market

• 13.1. Indonesia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bladder Cancer Drugs Market

• 14.1. South Korea Bladder Cancer Drugs Market Overview
• 14.2. South Korea Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bladder Cancer Drugs Market

• 15.1. Western Europe Bladder Cancer Drugs Market Overview
• 15.2. Western Europe Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bladder Cancer Drugs Market

• 16.1. UK Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bladder Cancer Drugs Market

• 17.1. Germany Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bladder Cancer Drugs Market

• 18.1. France Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bladder Cancer Drugs Market

• 19.1. Italy Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bladder Cancer Drugs Market

• 20.1. Spain Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bladder Cancer Drugs Market

• 21.1. Eastern Europe Bladder Cancer Drugs Market Overview
• 21.2. Eastern Europe Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bladder Cancer Drugs Market

• 22.1. Russia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bladder Cancer Drugs Market

• 23.1. North America Bladder Cancer Drugs Market Overview
• 23.2. North America Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bladder Cancer Drugs Market

• 24.1. USA Bladder Cancer Drugs Market Overview
• 24.2. USA Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bladder Cancer Drugs Market

• 25.1. Canada Bladder Cancer Drugs Market Overview
• 25.2. Canada Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bladder Cancer Drugs Market

• 26.1. South America Bladder Cancer Drugs Market Overview
• 26.2. South America Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bladder Cancer Drugs Market

• 27.1. Brazil Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bladder Cancer Drugs Market

• 28.1. Middle East Bladder Cancer Drugs Market Overview
• 28.2. Middle East Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bladder Cancer Drugs Market

• 29.1. Africa Bladder Cancer Drugs Market Overview
• 29.2. Africa Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bladder Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bladder Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Bladder Cancer Drugs Market Competitive Landscape
• 30.2. Bladder Cancer Drugs Market Company Profiles
  • 30.2.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Bladder Cancer Drugs Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Sanofi S.A.
• 31.3. F. Hoffmann-La Roche Ltd.
• 31.4. Novartis International AG
• 31.5. Johnson & Johnson
• 31.6. Merck & Co. Inc.
• 31.7. Vault Pharma Inc.
• 31.8. Vyriad Inc.
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Bayer AG
• 31.11. Asieris Pharmaceuticals Co. Ltd.
• 31.12. Asana BioSciences LLC
• 31.13. Array BioPharma Inc.
• 31.14. Archivel Farma S.L.
• 31.15. AndroScience Corporation

32. Global Bladder Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bladder Cancer Drugs Market

34. Recent Developments In The Bladder Cancer Drugs Market

35. Bladder Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Bladder Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bladder Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bladder Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer